US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics-Reference-Cited by-同舟云学术

US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics

Published:2011-02 Issue:4 Volume:3 Page:383-389
ISSN:1757-6180
Container-title:Bioanalysis
language:en
Short-container-title:Bioanalysis

Author:

Philip Reena,Carrington Lea¹,Chan Maria¹

Affiliation:

1. Division of Immunology and Hematology Devices, Office of In vitro Diagnostic Device Evaluation and Safety Center for Device and Radiological Health, Food and Drug Administration, 10903 New Hampshire Avenue, WO66, Room 5528, Silver Spring, MD 20993-0002, USA

Abstract

Recent advances in cancer therapy are based on agents that specifically target the products of the genes mutated in cancer cells. Development of companion diagnostic tests for these agents can simplify the drug-discovery process, make clinical trials more efficient and informative, and be used to individualize the therapy of cancer patients. Companion diagnostic development has many challenges. Examples include the reluctance of drug companies to restrict the use of their drugs through biomarker tests, difficulties of developing companion diagnostics from discovery to clinical validation, and the regulatory challenges in developing effective mechanisms to synchronize reviews of therapeutics with diagnostic devices used to personalize treatment. This article addresses the various challenges in developing companion diagnostics along with the US FDA’s approach to regulation of companion diagnostic devices.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Link

http://www.future-science.com/doi/pdf/10.4155/bio.11.1

Reference19 articles.

1. The US Food and Drug Administration perspective on cancer biomarker development

2. LiD, Hackett J, Chan MM, Penello G, Gutman SI. Regulatory aspects of the drug-diagnostics co-development process by proteomics. In:Current Proteomics: From Bench to Bedside. Sayed S, Daoud (Eds). Humana Press, Totowa, NJ, USA (2007).

3. FDA perspectives on pharmacogenetic testing

4. Food and Drug Administration Regulation of in Vitro Diagnostic Devices

5. LeskoL, Salerno RA.Workshop On Pharmacogenetics/Pharmacogenomics in Drug Development and Regulatory Decision-Making. Rockville, MD, USA, 16–17 May 2002.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Necessity of strengthening the current clinical regulatory for companion diagnostics: An institutional comparison of the FDA, EMA, and MFDS;Molecular Therapy - Methods & Clinical Development;2023-09

2. Circulating CD137+ T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients;International Journal of Molecular Sciences;2023-04-12

3. Structure-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation of EGFR for the Clinical Treatment of Glioblastoma;Applied Biochemistry and Biotechnology;2023-03-28

4. Drug discovery: Standing on the shoulders of giants;Managing the Drug Discovery Process;2023

5. Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity;Oral Oncology;2021-08